SCHEMBL19687429

SCHEMBL19687429

COCc1cc(NC2CC(F)(F)C2)nc(-n2nc(C)cc2C)n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.50
KCNN3 Q9UGI6 1/20 0.50
ALOX15 P16050 3/20 0.41
ADORA2A P29274 11/20 0.40
ADORA1 P30542 10/20 0.40
NPSR1 Q6W5P4 3/20 0.39
LMNA P02545 2/20 0.39
HIF1A Q16665 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2B P29275 1/20 0.39
POLB P06746 1/20 0.38
CYP2C19 P33261 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127078 1.00 KCNN2 (0.50) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL19686601 0.90 KCNN2 (0.54) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL31127124 0.88 KCNN3 (0.53) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL21143986 0.88 KCNN3 (0.53) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL31127085 0.87 KCNN2 (0.52) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL21143794 0.87 KCNN2 (0.52) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL19686434 0.84 KCNN2 (0.53) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL21143828 0.81 KCNN3 (0.55) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19687390 0.79 KCNN2 (0.51) KCNN2KCNN3ALOX15ADORA2AADORA1
SCHEMBL19686926 0.78 KCNN2 (0.55) KCNN2KCNN3ALOX15ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885ALOX15 2894/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885ALOX15 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.